Results 121 to 130 of about 800,324 (296)

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

open access: yesAdvanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu   +10 more
wiley   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

open access: yesAdvanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He   +6 more
wiley   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

open access: yesAdvanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang   +15 more
wiley   +1 more source

Univariate analysis of severe side effects during adjuvant chemotherapy.

open access: yes, 2016
Univariate analysis of severe side effects during adjuvant chemotherapy.
Tetsuro Tominaga (3387701)   +5 more
core   +1 more source

Distribution of the time to adjuvant chemotherapy in 977 patients.

open access: yes, 2020
Distribution of the time to adjuvant chemotherapy in 977 patients.
Gyoung Tae Noh (4524667)   +6 more
core   +1 more source

Acoustically Activatable Drug‐Loaded Nanodroplets for Mechanochemical Therapy in Solid Tumors

open access: yesAdvanced Science, EarlyView.
Microfluidically fabricated drug‐loaded nanodroplets are sequentially activated by dual‐frequency ultrasound through acoustic droplet vaporization followed by bubble collapse, enabling spatially controlled drug release and mechanical tumor fractionation, resulting in synergistic mechanochemotherapy and prolonged survival.
Tiran Bercovici   +4 more
wiley   +1 more source

Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation

open access: yesAdvanced Science, EarlyView.
Incomplete microwave ablation induces animmunosuppressive microenvironment in tumor‐draining lymph nodes. An albumin‐based lipoprotein nanosystem enables coordinated delivery of immunomodulators to tumor‐draining lymph nodes and residual tumors, reverses post‐ablation immunosuppression, suppresses residual tumor growth, and promotes durable antitumor ...
Xuexia Shan   +14 more
wiley   +1 more source

Adjuvant Chemotherapy in Primary Breast Cancer

open access: yes, 2006
Adjuvant systemic chemotherapy reduces the risk of relapse by about 25%. In hormone receptor-negative tumors, adjuvant chemotherapy is considered standard, independent of age or lymph node status.
Harbeck, Nadia;Minckwitz, Gunter von
core   +1 more source

Home - About - Disclaimer - Privacy